TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02225873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor control exercises
Description: Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muscle strength-endurance and proprioception
Description: Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
Study: NCT02123563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrason Essential oils rinse
Description: Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrason Placebo rinse
Description: Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
Study: NCT02345824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 INHIBITOR
Study: NCT02523950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens (IOL) implantation
Description: After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens (IOL) implantation
Description: After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
Study: NCT03274765

Intervention type: DIAGNOSTIC_TEST
Intervention: Dosage of oestradiol
Description: The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation.
Study: NCT01707537

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Euvichol
Description: 1.5mL/vial, 1vial at 2-week intervals twice
Study: NCT02805140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual exercise
Description: Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile apps
Description: During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise resources and information
Description: For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise resources and information
Description: For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
Study: NCT02383316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose tolerance test
Description: Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
Study: NCT06007118

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Description: accelerated whole breast irradiation with the boost to tumor bed (15x 2,67 Gy + 5x 2,0 Gy, every working day)
Study: NCT02185300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pediatric Granules
Description: Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pediatric Granules
Description: Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pediatric Granules
Description: Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir Pediatric Granules
Description: Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
Study: NCT04510350

Intervention type: OTHER
Intervention: Biomarkers analysis
Description: Genetic analysis of regions of interest

Intervention type: OTHER
Intervention: Biomarkers analysis
Description: Genetic analysis of regions of interest
Study: NCT01219517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polar body and embryo biopsy
Description: 2 polar bodies and all embryos will be biopsied prior to embryo transfer.
Study: NCT03454789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block for LB Group
Description: Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block for BS Group
Description: Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block for LS Group
Description: Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brachial plexus block for BL Group
Description: Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
Study: NCT03857776

Intervention type: OTHER
Group type: OTHER
Intervention: Open dialogue about complementary alternative medicine
Description: 1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Standard care including referral to a homepage about CAM
Study: NCT02468830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
Study: NCT02220634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Injection for intravenous administration
Study: NCT00016276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study: NCT00334594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
Study: NCT01621672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: 10 mg/day in the morning same time each day
Study: NCT00016276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study: NCT03488914

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: YMHP Intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Study: NCT03001310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV - CNGB3
Description: Comparison of different dosages of AAV-CNGB3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV - CNGB3
Description: Comparison of different dosages of AAV-CNGB3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV - CNGB3
Description: Comparison of different dosages of AAV-CNGB3
Study: NCT01357915

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects.
Study: NCT00016276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study: NCT01357915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK149203A
Description: GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
Study: NCT02235987

Intervention type: DRUG
Group type: OTHER
Intervention: octreotide
Description: Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.

Intervention type: DRUG
Group type: OTHER
Intervention: DG3173
Description: Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Study: NCT02093234

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile health care application
Description: mobile health application for cell phones to assist patients in managing their diabetes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHWs and mobile health care application
Description: CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker (CHW)
Description: CHWs assist patients in managing their diabetes in various ways.
Study: NCT02391350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and re-assurance
Description: Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
Study: NCT00334594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic conventional surgery
Description: Extrapleural pneumonectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic conventional surgery
Description: Extrapleural pneumonectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
Study: NCT00304135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study: NCT00016276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03965637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
Study: NCT00962988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cost-Free Pharmacotherapy Group
Description: Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Prescription Only Group
Description: Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
Study: NCT04546932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung-protective mechanical ventilation
Description: Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
Study: NCT00974948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac plexus neurolysis
Description: Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
Study: NCT03376620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1,4-Diaminobutane
Description: Daily application to surgical breast scars of 1,4 diaminobutane on the active side

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 10% Urea cream
Description: Daily application to surgical breast scars of 10% Urea cream on the sham side
Study: NCT01431352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine granules or Chinese herbal medicine granules placebo
Description: twice a day for 6 month
Study: NCT03352141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT03821363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
Study: NCT04649450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
Study: NCT03917511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic training with mirror therapy
Description: Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robotic-assisted training
Description: The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
Study: NCT02172352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba 679 BR low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba 679 BR middle dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ba 679 BR high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder